Hypertrophic Cardiomyopathy Clinical Trial

Exercise Intolerance in Non-obstructive Hypertrophic Cardiomyopathy

Summary

The EXCITE-HCM study is a randomized, controlled, blinded clinical trial designed to evaluate the effect of moderate intensity exercise training versus usual physicial activity on the improvement of HCM-related symptoms and cardiac function. About 70 participants will be recruited and randomized on a 1:1 ratio to either moderate intensity training or usual physicial activity interventions. Patients will be followed during a period of 24 weeks and assesesments as physical examination, questionnaires, 12 lead ecg's, biomarker levels, echocardiogram, Cardiac Magnetic resonance, PET and CPET will be performed to evaluate their response to the intervention.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Patients 18 to 80 years of age with diagnosis of hypertrophic cardiomyopathy1 defined by left ventricular hypertrophy with end-diastolic wall thickness 15 mm or greater on 2D echocardiography in the absence of other primary causes of left ventricular hypertrophy or wall thickness between 13 and 15 mm in the presence of other features suggestive of hypertrophic cardiomyopathy, such as systolic anterior motion of the mitral valve leaflets, family history of hypertrophic cardiomyopathy, or positive genetic test result.
Left ventricular outflow tract gradient <30 mmHg at rest and with provocation.
Left ventricular ejection fraction ≥ 50% by biplane Simpson's method.
Access to exercise equipment at home or at a fitness center.
Ability to complete study related testing including online surveys and smart phone use
Ability to perform 24 weeks of exercise training

Exclusion Criteria:

History of exercise-induced syncope or ventricular arrhythmias
LVOT obstruction being evaluated for septal reduction therapy; less than 3 months after
History of septal reduction therapy - surgery or ablation
History of ICD placement in the previous 3 months
History of hypotensive response with exercise testing (>20 mm Hg decrease of systolic blood pressure from baseline blood pressure or an initial increase in systolic blood pressure followed by a decrease of systolic blood pressure >20 mm Hg)
Clinical decompensation in the previous 3 months, defined as New York Heart Association class IV congestive heart failure symptoms or Canadian Cardiovascular Society class IV angina symptoms
Left ventricular ejection fraction less than 50% by echocardiography
Life expectancy less than 12 months
Pregnant or planned pregnancy
Inability to exercise owing to any medical or other limitations
Unwillingness to refrain from competitive sports, burst activity, or heavy isometric exercise for the duration of the study, if assigned to the non-exercise group.

Study is for people with:

Hypertrophic Cardiomyopathy

Estimated Enrollment:

70

Study ID:

NCT05818605

Recruitment Status:

Recruiting

Sponsor:

University of California, San Francisco

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

University of California - San Francisco
San Francisco California, 94143, United States More Info
Cynthia Partida-Higuera, CCRP
Contact
415-514-1125
[email protected]
Theodore P Abraham, M.D
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Hypertrophic Cardiomyopathy

Estimated Enrollment:

70

Study ID:

NCT05818605

Recruitment Status:

Recruiting

Sponsor:


University of California, San Francisco

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.